Other names
2-Guanidinoacetic acid
352-97-6 YesY
3D model (Jmol) Interactive image
Interactive image
3DMet B00139
ChemSpider 743 N
DrugBank DB02751 N
ECHA InfoCard 100.005.936
EC Number 206-529-5
KEGG C00581 N
MeSH glycocyamine
PubChem 763
Molar mass 117.11 g·mol−1
Appearance White crystals
Odor Odourless
Melting point 300 °C (572 °F; 573 K)
log P −1.11
Acidity (pKa) 3.414
Basicity (pKb) 10.583
GHS pictograms
GHS signal word WARNING
H315, H319, H335
P261, P305+351+338
R-phrases R36/37/38
S-phrases S26, S36
Related compounds
Related alkanoic acids
Related compounds
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Glycocyamine (or guanidinoacetate) is a metabolite of glycine in which the amino group has been converted into a guanidine.

Glycocyamine is a direct precursor of creatine and is used as a supplement. However the metabolism of creatine from glycocyamine in the liver causes a depletion of methyl groups. This causes homocysteine levels to rise, which has been shown to produce cardiovascular and skeletal problems.


A series of studies showed that a combination of betaine and glycocyamine improves the symptoms of patients with chronic illness, including heart disease, without toxicity. Betaine can provide a methyl group to glycocyamine, via methionine, for the formation of creatine. [1] In overall, such treatment led to less fatigue, greater strength and endurance, and an improved sense of well-being. The patients with cardiac decompensation (arteriosclerosis or rheumatic disease) [2] and congestive heart failure [3] had improved cardiac function. The patients gained weight (improved nitrogen balance) and saw lessened symptoms of arthritis and asthma and increased libido, and those people suffering from hypertension experienced transient reduced blood pressure. Also the studies shows the increase of glucose tolerance in both diabetic subjects and subjects without diabetes. [4]


  1. Borsook H, Borsook ME. The biochemical basis of betaine-glycocyamine therapy. Ann West Med Surg 1951;5:825–9.
  2. Borsook ME, Borsook H. Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg 1951;5:830–55.
  3. Van Zandt V, Borsook H. New biochemical approach to the treatment of congestive heart failure. Ann West Med Surg 1951;5:856–62.
  4. Stuart AS Craig (September 2004). "Betaine in human nutrition". American Journal of Clinical Nutrition. 80 (3): 539–549. PMID 15321791. Retrieved 2010-02-10.

See also

This article is issued from Wikipedia - version of the 6/24/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.